Glaukos Corporation (NYSE:GKOS - Get Free Report) COO Joseph Gilliam sold 44,917 shares of the firm's stock in a transaction on Thursday, November 12th. The shares were sold at an average price of $246.32, for a total value of $11,063,955.44. Following the sale, the chief operating officer directly owned 71,602 shares of the company's stock, valued at $17,637,004.64. This represents a 38.55% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Glaukos Trading Down 0.3%
Shares of GKOS opened at $245.03 on Tuesday. The stock has a fifty day moving average price of $185.95 and a two-hundred day moving average price of $147.70. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.09 and a current ratio of 4.57. Glaukos Corporation has a 52-week low of $87.32 and a 52-week high of $255.18. The company has a market cap of $14.51 billion, a price-to-earnings ratio of -83.34 and a beta of 0.68.
Glaukos (NYSE:GKOS - Get Free Report) last posted its quarterly earnings data on Wednesday, October 28th. The medical instruments supplier reported $0.47 EPS for the quarter, topping analysts' consensus estimates of ($0.10) by $0.57. The company had revenue of $211.03 million for the quarter, compared to analyst estimates of $168.04 million. Glaukos had a negative return on equity of 0.97% and a negative net margin of 24.60%. The business's revenue was up 58.0% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.16) earnings per share. Analysts predict that Glaukos Corporation will post 0.50 EPS for the current fiscal year.
Analyst Upgrades and Downgrades
A number of research analysts recently issued reports on GKOS shares. Zacks Research raised Glaukos from a "hold" rating to a "strong-buy" rating in a report on Wednesday, October 28th. Wells Fargo & Company upped their price target on shares of Glaukos from $178.00 to $226.00 and gave the stock an "overweight" rating in a research report on Thursday, October 29th. Citigroup increased their price objective on shares of Glaukos from $225.00 to $247.00 and gave the stock a "buy" rating in a report on Thursday, October 29th. HC Wainwright raised their price objective on shares of Glaukos from $195.00 to $248.00 and gave the company a "buy" rating in a research report on Thursday, October 29th. Finally, UBS Group assumed coverage on shares of Glaukos in a research note on Tuesday, July 28th. They issued a "neutral" rating and a $150.00 target price for the company. One research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $218.00.
Get Our Latest Stock Report on Glaukos
Institutional Inflows and Outflows
Institutional investors have recently bought and sold shares of the stock. Goldman Sachs Group Inc. boosted its position in Glaukos by 14.4% in the 3rd quarter. Goldman Sachs Group Inc. now owns 1,025,937 shares of the medical instruments supplier's stock valued at $168,449,000 after buying an additional 128,916 shares during the last quarter. Soleus Capital Management L.P. acquired a new stake in shares of Glaukos in the 3rd quarter valued at $4,195,000. Cetera Investment Advisers raised its position in shares of Glaukos by 6.1% during the third quarter. Cetera Investment Advisers now owns 3,402 shares of the medical instruments supplier's stock worth $559,000 after acquiring an additional 197 shares during the last quarter. Entropy Technologies LP bought a new stake in shares of Glaukos during the third quarter worth $402,000. Finally, Jump Financial LLC bought a new stake in shares of Glaukos during the third quarter worth $2,014,000. Institutional investors own 99.04% of the company's stock.
Glaukos Company Profile
(
Get Free Report)
Glaukos Corporation is an ophthalmic medical technology company that develops and commercializes treatments for glaucoma and other eye disorders. Its portfolio includes minimally invasive glaucoma surgery (MIGS) devices, such as the iStent family, and iDose TR, an implant designed to deliver glaucoma medication inside the eye over an extended period. The company also offers products for corneal disorders, including technology used in corneal cross-linking procedures to treat keratoconus and other conditions that weaken the cornea.
Recommended Stories

This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].